Health Care · Biological Products, (No Diagnostic Substances)

MRNA Moderna SEC Filings & Insider Trading Activity 2026

company
CIK 1682852108 filings
S&P 500

MRNA at a glance

Moderna (MRNA, SEC CIK 1682852) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Moderna (MRNA) reported revenue of $1.9 billion (down 39.9% from FY2024) and a net loss of $2.8 billion. Diluted EPS was -$7.26.
  • As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Moderna (MRNA) shares worth $24.4 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Hoge Stephen on November 17, 2026 of 5,082 shares at $212.57 per share.
  • In the last 90 days, MRNA insiders reported 0 open-market purchases ($0) and 12 open-market sales ($50.8M) on Form 4, a net sale of $50.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$1.9B
−39.9% vs prior year
Insiders · 90 days
0 buys · 12 sells
Net −$50.8M
13F holders
38 funds
$24.4B · −2 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 1.01 · Item 2.03

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Development and commercialization of mRNA-based vaccines and therapeutics across infectious diseases, oncology, and rare diseases
  • New product: Launch of mNEXSPIKE COVID vaccine in Q3 2025, now leading US retail product; ongoing filings for flu+COVID and flu-only vaccines in multiple regions
  • Strategic shift: Geographic expansion with three new Moderna-managed manufacturing sites in UK, Canada, Australia; partnership with Recordati for rare disease mRNA-3927 development
  • Quantitative metric: 2025 revenue $1.9B, primarily from COVID vaccines; eight Phase 2/3 oncology trials on intismeran autogene in collaboration with Merck underway
  • Noteworthy fact: First FDA acceptance of amended BLA for seasonal flu vaccine (mRNA-1010) with PDUFA date August 5, 2026, after Type A meeting and revised regulatory pathway

Risk Factors

  • Regulatory risk: FDA refusal-to-file letter on seasonal flu vaccine mRNA-1010; amended BLA accepted with PDUFA date August 5, 2026
  • Geopolitical risk: COVID and RSV vaccine manufacturing now onshored in US, Australia, UK, and Canada under government agreements for local supply and pandemic preparedness
  • Operational risk: mRNA-1010 flu vaccine regulatory review delays following FDA Type A meeting and need for additional study in older adults
  • Competitive risk: Collaboration with Merck on intismeran autogene (mRNA-4157) immunotherapy facing competition from other checkpoint inhibitors like KEYTRUDA
  • Financial risk: $1.5 billion five-year credit facility entered November 2025, including $600 million funded initial term loan, adding leverage and interest expense burden

Management Discussion & Analysis

  • Revenue $1.944B, down 40% YoY ($3.236B in 2024); net product sales $1.818B, down 42% YoY ($3.109B in 2024) due to lower COVID vaccine demand
  • Operating loss $3.074B vs $3.945B; cost of sales $868M (48% of net product sales) vs $1.464B (47%); R&D $3.132B down 31%, SG&A $1.018B down 13%
  • Best segment: Other revenue stable at $126M; worst segment: Net product sales down $1.29B driven by COVID vaccine decline
  • Net cash used in operations $1.873B (improved from $3.004B); capex $192M; financing proceeds $593M including $578M credit facility draw; cash & investments $8.135B down 15%
  • Management expects product sales growth in 2026 from strategic partnerships and mNEXSPIKE uptake; anticipates modest R&D reductions and stable SG&A; identifies COVID market decline as ongoing risk

AI summary of the MRNA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added convertible-notes risk, triggered by issuance of 0.00% Convertible Senior Notes due 2032
  • Liquidity risk: insufficient cash or financing for maturity repayment, conversion settlements, or fundamental-change repurchases
  • Default risk: credit agreement restrictions could prevent cash payments required under the notes’ indenture
  • Dilution risk: share-based conversion may dilute stockholders and pressure common-stock prices
  • Counterparty risk: uncapped exposure to financial institutions under unsecured capped call transactions

AI summary of the MRNA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • Interest margins reduced 0.75 percentage points, to 4.75% SOFR-based and 3.75% base-rate loans
  • Term-loan maturity extended one year, from November 24, 2030 to November 24, 2031

Item 2.03: Creation of a Direct Financial Obligation

  • Item 2.03 points to Item 1.01 for the terms of Moderna’s new direct financial obligation
  • Investors should review Item 1.01 for obligation amount, maturity, interest rate, and purpose
Filed Nov 13, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Chief Legal Officer Shannon Thyme Klinger retiring, employment continuing through March 31, 2027
  • Officer resignation effective March 31, 2027, or earlier at Moderna’s designation
Filed Nov 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Moderna announced third-quarter 2026 financial results for the period ended September 30, 2026
  • Exhibit 99.1 contains the detailed earnings release for revenue, profitability, and outlook analysis

Item EX-99.1: Item EX-99.1

  • Q3 revenue $1.3B, up 29%, with international COVID vaccine sales driving growth
  • GAAP net income $162M, diluted EPS $0.38, reversing Q3 2025’s $200M loss

AI summaries of MRNA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MRNA

Don't miss the next MRNA filing

  • Alerts as it files. A push when MRNA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MRNA, by share count.
  • Ask anything. An AI agent that reads every MRNA filing and answers with sources.

MRNA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hoge StephenSellNov 17, 2026$212.57
Hoge StephenMNov 17, 2026-
Hoge StephenMNov 17, 2026$12.21
Hoge StephenSellNov 17, 2026$211.45
Hoge StephenSellNov 17, 2026$214.19
Hoge StephenMNov 16, 2026-
Hoge StephenSellNov 16, 2026$219.66
Hoge StephenMNov 16, 2026$12.21

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$3.2B$1.9B
Operating Income--$3.9B-$3.1B
Net Income-$4.7B-$3.6B-$2.8B
Op. Margin--121.9%-158.1%
Net Margin--110.0%-145.2%
Balance Sheet
Total Assets-$14.1B$12.3B
Equity$13.9B$10.9B$8.7B
ROE-34.0%-32.7%-32.6%
Per Share
EPS$-12.33$-9.28$-7.26
Cash Flow
Operating CF--$3.0B-$1.9B
CapEx$707.0M$1.1B$192.0M

Source: XBRL data in Moderna (MRNA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MRNA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MRNA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202638$24.38B
Q2 202640$13.04B
Q1 202639$8.92B
Q4 202535$5.70B
Q3 202534$4.53B
Q2 202534$4.83B
Q1 202534$3.81B
Q4 202430$4.49B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 284 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MRNA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
8-KNov 16, 2026Analysis-
8-KNov 13, 2026Analysis-
4Nov 9, 2026--
8-KNov 6, 2026Analysis-
10-QNov 6, 2026Analysis
4Oct 16, 2026--
4Oct 7, 2026--
8-KSep 30, 2026Analysis-
4Sep 16, 2026--
4Sep 14, 2026--
4Sep 8, 2026--
4Sep 8, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
8-KSep 1, 2026Analysis-
4Aug 31, 2026--
4Aug 31, 2026--
4Aug 31, 2026--
SC 13GAug 12, 2026-
4Aug 7, 2026--
8-KJul 31, 2026Analysis-
10-QJul 31, 2026Analysis
4Jul 16, 2026--

Related Health Care companies

All Health Care →

MRNA SEC filings: frequently asked questions

Are MRNA insiders buying or selling?

In the last 90 days, Moderna (MRNA) officers, directors and 10% owners reported no open-market purchases and 12 open-market sales worth $50.8 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MRNA stock?

As of September 30, 2026, the largest Moderna (MRNA) holders among the 13F filers tracked by SignalX were BlackRock ($5.4 billion), Vanguard Capital Management LLC ($4.6 billion), Vanguard Portfolio Management LLC ($3.0 billion), State Street Corp ($3.0 billion), T. Rowe Price Group ($1.5 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MRNA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Moderna (MRNA) reported revenue of $1.9 billion (down 39.9% from FY2024) and a net loss of $2.8 billion. Diluted EPS was -$7.26. The figures come from the XBRL data in the 10-K.

What are the main risks in MRNA's latest 10-K?

In the 10-K filed February 20, 2026, Moderna (MRNA) flagged: Regulatory risk: FDA refusal-to-file letter on seasonal flu vaccine mRNA-1010; amended BLA accepted with PDUFA date August 5, 2026. Geopolitical risk: COVID and RSV vaccine manufacturing now onshored in US, Australia, UK, and Canada under government agreements for local supply and pandemic preparedness. (AI summary of the Risk Factors section.)

What did MRNA report in its latest 8-K?

Moderna (MRNA) filed an 8-K on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 2.03 (Creation of a Direct Financial Obligation). Interest margins reduced 0.75 percentage points, to 4.75% SOFR-based and 3.75% base-rate loans.

What are the latest MRNA SEC filings?

Moderna (MRNA) filed its latest 10-K annual report on February 20, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 18, 2026.

What is MRNA's SEC CIK number?

Moderna (MRNA)'s SEC Central Index Key (CIK) is 1682852. EDGAR lists every MRNA filing under that number.

Ask anything about MRNA

The research agent reads MRNA's filings, financials, insider trades and 13F holders, then answers with sources.